Skip to main content

Research Repository

See what's under the surface

Advanced Search

Allogeneic stem cell transplantation in patients with atypical chronic myeloid leukaemia: a retrospective study from the Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplantation

Onida, Francesco; De Wreede, Lliesbeth C.; van Blezan, Anja; Elkema, Diderik-Jan; Byrne, Jenny L.; Iori, Anna P.; Schots, Rick; Jungova, Alexandra; Schetelig, Johannes; Finke, Juergen; Veelken, Hendrick; Johanssen, Jan-Erik; Craddock, Charles; Stellies, Matthias; Theobald, Matthias; Holler, Ernst; Schanz, Urs; Schaap, Nicolaas; Bittenbring, Joerg; Olivaria, Eduardo; Chalandan, Yves; Kroger, Nicolaus; the Myeloproliferative Neoplasm Subcommittee of the Chronic Malignancies Working Party

Authors

Francesco Onida fonida@gmail.com

Lliesbeth C. De Wreede

Anja van Blezan

Diderik-Jan Elkema

Jenny L. Byrne

Anna P. Iori

Rick Schots

Alexandra Jungova

Johannes Schetelig

Juergen Finke

Hendrick Veelken

Jan-Erik Johanssen

Charles Craddock

Matthias Stellies

Matthias Theobald

Ernst Holler

Urs Schanz

Nicolaas Schaap

Joerg Bittenbring

Eduardo Olivaria

Yves Chalandan

Nicolaus Kroger

the Myeloproliferative Neoplasm Subcommittee of the Chronic Malignancies Working Party



Abstract

Atypical chronic myeloid leukaemia (aCML) is an aggressive malignancy for which allogeneic haematopoietic stem cell transplantation (allo-HSCT) represents the only curative option. We describe transplant outcomes in 42 patients reported to the European Society for Blood and Marrow Transplantation (EBMT) registry who underwent allo-HSCT for aCML between 1997 and 2006. Median age was 46 years. Median time from diagnosis to transplant was 7 months. Disease status was first chronic phase in 69%. Donors were human leucocyte antigen (HLA)-identical siblings in 64% and matched unrelated (MUD) in 36%. A reduced intensity conditioning was employed in 24% of patients. T-cell depletion was applied in 87% and 26% of transplants from MUD and HLA-identical siblings, respectively. According to the EBMT risk-score, 45% of patients were ‘low-risk’, 31% ‘intermediate-risk’ and 24% ‘high-risk’. Following allo-HSCT, 87% of patients achieved complete remission. At 5 years, relapse-free survival was 36% and non-relapse mortality (NRM) was 24%, while relapse occurred in 40%. Patient age and the EBMT score had an impact on overall survival. Relapse-free survival was higher in MUD than in HLA-identical sibling HSCT, with no difference in NRM. In conclusion, this study confirmed that allo-HSCT represents a valid strategy to achieve cure in a reasonable proportion of patients with aCML, with young patients with low EBMT risk score being the best candidates.

Journal Article Type Article
Publication Date 2017-06
Journal British Journal of Haematology
Print ISSN 0007-1048
Electronic ISSN 2836-9779
Publisher Wiley
Peer Reviewed Peer Reviewed
Volume 177
Issue 5
Pages 759-765
APA6 Citation the Myeloproliferative Neoplasm Subcommittee of the Chronic Malignancies Working Party, , Kröger, N., Chalandon, Y., Olavarria, E., Bittenbring, J., Stelljes, M., …Kroger, N. (2017). Allogeneic stem cell transplantation in patients with atypical chronic myeloid leukaemia: a retrospective study from the Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplantation. British Journal of Haematology, 177(5), 759-765. https://doi.org/10.1111/bjh.14619
DOI https://doi.org/10.1111/bjh.14619
Keywords allogeneic transplantation, atypical chronic myeloid leukaemia, Myelodyslastic/Myeloproliferative Neoplasms (MDS/MPN), Ph-negative CML:BCR-ABL1-negative
Publisher URL http://onlinelibrary.wiley.com/doi/10.1111/bjh.14619/abstract
Copyright Statement Copyright information regarding this work can be found at the following address: http://eprints.nottingh.../end_user_agreement.pdf
Additional Information This is the pre-peer reviewed version of the following article:Onida, F., de Wreede, L. C., van Biezen, A., Eikema, D.-J., Byrne, J. L., Iori, A. P., Schots, R., Jungova, A., Schetelig, J., Finke, J., Veelken, H., Johansson, J.-E., Craddock, C., Stelljes, M., Theobald, M., Holler, E., Schanz, U., Schaap, N., Bittenbring, J., Olavarria, E., Chalandon, Y., Kröger, N. and the Myeloproliferative Neoplasm Subcommittee of the Chronic Malignancies Working Party (2017), Allogeneic stem cell transplantation in patients with atypical chronic myeloid leukaemia: a retrospective study from the Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplantation. Br J Haematol, 177: 759–765. doi:10.1111/bjh.14619, which has been published in final form at http://onlinelibrary.wi...111/bjh.14619/abstract. This article may be used for non-commercial purposes in accordance with Wiley Terms and Conditions for Self-Archiving

Files

Onida_et_al-2017-British_Journal_of_Haematology (1).pdf (284 Kb)
PDF

Copyright Statement
Copyright information regarding this work can be found at the following address: http://eprints.nottingham.ac.uk/end_user_agreement.pdf





You might also like



Downloadable Citations

;